Veratryl alcohol Clinical Trials

Size	Price	Qty
100mg	USD 97

Clinical Trials

Several clinical trials are registered to evaluate conditions including obstructive sleep apnea, advanced liver disease, intervertebral disc degeneration with back pain, and antibiotic pharmacokinetics during extracorporeal membrane oxygenation for cardiogenic shock or post-cardiac surgery. Sponsored by organizations such as Astes, the VA Office of Research and Development, and University Hospital Grenoble, these Phase Not Applicable or unassigned studies are currently listed as not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05711329	Not yet recruiting	Obstructive Sleep Apnea	Astes	2024-11-01	--
NCT06068491	Not yet recruiting	Liver Diseases	VA Office of Research and Development	2024-10-01	Not Applicable
NCT04134910	Not yet recruiting	Back Pain\|Intervertebral Disc Degeneration	VA Office of Research and Development	2024-10-01	Not Applicable
NCT06338345	Not yet recruiting	Cardiogenic Shock\|Post-cardiac Surgery\|Cardiac Arrest\|Extracorporeal Membrane Oxygenation Complication\|Infections	University Hospital Grenoble	2024-09-01	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Veratryl alcohol product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Veratryl alcohol acts as a natural substrate for fungal lignin peroxidase, undergoing enzymatic oxidation to generate active radical cation intermediates that drive the oxidative cleavage of complex aromatic polymers. Understanding these substrate-peroxidase dynamics provides critical biochemical insights into redox processing and oxidative stress mechanisms relevant to clinical conditions such as liver disease and intervertebral tissue degeneration.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).